Tnf Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Q/C Technologies, Inc. calls a Special Meeting to approve a highly dilutive capital raise, an expanded equity incentive plan, and a reverse stock split to maintain Nasdaq listing.
TNF Pharmaceuticals seeks stockholder approval for a reverse stock split to meet Nasdaq listing requirements, an increase in authorized shares for future financing, and an adjustment to the stated value of preferred stock.
DEF: TNF Pharmaceuticals Proposes Reverse Stock Split and Share Increase to Regain Nasdaq Compliance
TNF Pharmaceuticals is seeking stockholder approval for a reverse stock split and an increase in authorized shares to meet Nasdaq listing requirements and enhance financial flexibility.
TNF Pharmaceuticals is asking stockholders to approve an amendment to its 2021 Equity Incentive Plan to increase the number of shares available for grant by 2,259,060.
DEF 14A: MyMD Pharmaceuticals Seeks Stockholder Approval for Share Issuance and Increase in Authorized Shares
MyMD Pharmaceuticals is holding a special meeting to seek stockholder approval for issuing shares related to recent financing agreements and to increase the number of authorized shares of common stock.